Luke L. Lairson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luke L. Lairson has a total of 420 co-authors. Here are the top co-authors by number of shared publications:
- Costas Andreas Lyssiotis
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, USA
12 shared publications - Peter G. Schultz
Department of Chemistry, Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
12 shared publications Emily N. Chin
Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
8 shared publications- Warren W. Wakarchuk
University of Alberta
8 shared publications - Shoutian Zhu
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, CA 92037, USA
6 shared publications Brittney A. Beyer
Department of Chemistry, The Scripps Research Institute
5 shared publications
Latest Publications
- Open Access
- 11 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Distinct oligomeric assemblies of STING induced by non-nucleotide agonists
STING plays essential roles coordinating innate immune responses to processes that range from pathogenic infection to genomic instability. Its adaptor function is activated by cyclic dinucleotide (CDN) secondary messengers originating from self (2’3’-cGAMP) or bacterial sources (3’3’-CDNs). Different classes of CDNs possess distinct binding modes, stabilizing STING’s ligand-binding domain (LBD) in either a closed or open conformation. The closed conformation, induced by the endogenous ligand 2’3’-cGAMP, has been extensively studied using cryo-EM. However, significant questions remain regarding the structural basis of STING activation by open conformation-inducing ligands. Using cryo-EM, we investigate potential differences in conformational changes and oligomeric assemblies of STING for closed and open conformation-inducing synthetic agonists. While we observe a characteristic 180° rotation for both classes, the open-LBD inducing agonist diABZI-3 uniquely induces a quaternary structure reminiscent but distinct from the reported autoinhibited state of apo-STING. Additionally, we observe slower rates of activation for this ligand class in functional assays, which collectively suggests the existence of a potential additional regulatory mechanism for open conformation-inducing ligands that involves head-to-head interactions and restriction of curved oligomer formation. These observations have potential implications in the selection of an optimal class of STING agonist in the context of a defined therapeutic application.
- 11 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessDistinct oligomeric assemblies of STING induced by non-nucleotide agonists
STING plays essential roles coordinating innate immune responses to processes that range from pathogenic infection to genomic instability. Its adaptor function is activated by cyclic dinucleotide (CDN) secondary messengers originating from self (2’3’-cGAMP) or bacterial sources (3’3’-CDNs). Different classes of CDNs possess distinct binding modes, stabilizing STING’s ligand-binding domain (LBD) in either a closed or open conformation. The closed conformation, induced by the endogenous ligand 2’3’-cGAMP, has been extensively studied using cryo-EM. However, significant questions remain regarding the structural basis of STING activation by open conformation-inducing ligands. Using cryo-EM, we investigate potential differences in conformational changes and oligomeric assemblies of STING for closed and open conformation-inducing synthetic agonists. While we observe a characteristic 180° rotation for both classes, the open-LBD inducing agonist diABZI-3 uniquely induces a quaternary structure reminiscent but distinct from the reported autoinhibited state of apo-STING. Additionally, we observe slower rates of activation for this ligand class in functional assays, which collectively suggests the existence of a potential additional regulatory mechanism for open conformation-inducing ligands that involves head-to-head interactions and restriction of curved oligomer formation. These observations have potential implications in the selection of an optimal class of STING agonist in the context of a defined therapeutic application.
- 10 February 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (2) , 442-454
Insights into Free Drug Release from Efficacious N-Acyl O-Aminophenol Duocarmycin Prodrugs
Acyclic and cyclic N-acyl O-aminophenol prodrugs of duocarmycin analogues were reported as members of a unique class of reductively cleaved prodrugs that map seamlessly onto the duocarmycin family of natural products. Although these prodrugs were explored with the expectations that they may be cleaved selectively within hypoxic tumor environments that have intrinsically higher concentrations of reducing nucleophiles, the remarkable stability of some such prodrugs suggests another mechanism of free drug release is operative. The prototype of such chemically unreactive N-acyl O-aminophenol prodrugs is 1, which proved remarkably efficacious in vivo in vertebrate tumor models; was found to lack the toxicity that is characteristic of traditional chemotherapeutic drugs as well as the free drugs in the class (e.g., myelosuppression); and displayed a preferential site (intracellular), a slow and sustained rate, and a potentially unique mechanism of free drug release. Herein, we detail studies that provide insights into this stereoselective mechanism of free drug release. Combined, the results of the studies are consistent with an exclusive protein-mediated (enantio)selective activation and free drug release from prodrug 1 by N-O bond cleavage preferentially in cancer cell lines versus cultured normal human cell lines effected by a cytosolic cysteine-based enzyme and suggest that the activating protein is one that is selectively expressed, upregulated, or preferentially activated in cancer cell lines, potentially constituting a new oncology targeted precision therapy.
- 10 February 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (2) , 442-454
Insights into Free Drug Release from Efficacious N-Acyl O-Aminophenol Duocarmycin Prodrugs
Acyclic and cyclic N-acyl O-aminophenol prodrugs of duocarmycin analogues were reported as members of a unique class of reductively cleaved prodrugs that map seamlessly onto the duocarmycin family of natural products. Although these prodrugs were explored with the expectations that they may be cleaved selectively within hypoxic tumor environments that have intrinsically higher concentrations of reducing nucleophiles, the remarkable stability of some such prodrugs suggests another mechanism of free drug release is operative. The prototype of such chemically unreactive N-acyl O-aminophenol prodrugs is 1, which proved remarkably efficacious in vivo in vertebrate tumor models; was found to lack the toxicity that is characteristic of traditional chemotherapeutic drugs as well as the free drugs in the class (e.g., myelosuppression); and displayed a preferential site (intracellular), a slow and sustained rate, and a potentially unique mechanism of free drug release. Herein, we detail studies that provide insights into this stereoselective mechanism of free drug release. Combined, the results of the studies are consistent with an exclusive protein-mediated (enantio)selective activation and free drug release from prodrug 1 by N-O bond cleavage preferentially in cancer cell lines versus cultured normal human cell lines effected by a cytosolic cysteine-based enzyme and suggest that the activating protein is one that is selectively expressed, upregulated, or preferentially activated in cancer cell lines, potentially constituting a new oncology targeted precision therapy.
- Open Access
- 17 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 6 (2) , 273-280
Induced cell phenotype activity recording of DNA-tagged ligands
A generalizable methodology for recording and retrieving the phenotype-inducing activity of DNA-encoded ligands.
- 17 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 6 (2) , 273-280
Open AccessInduced cell phenotype activity recording of DNA-tagged ligands
A generalizable methodology for recording and retrieving the phenotype-inducing activity of DNA-encoded ligands.
- 7 November 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 115, 130007
Cladophorol-A is an inhibitor of cyclic GMP-AMP synthase
- 7 November 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 115, 130007
Cladophorol-A is an inhibitor of cyclic GMP-AMP synthase
- Top Cited Papers
- 21 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6702) , 1315-+
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti–PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of immune checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.
- 21 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6702) , 1315-+
Top Cited PapersJAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti–PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of immune checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.
- 20 January 2024
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 63 (3) , 251-263
Human Hsp70 Substrate-Binding Domains Recognize Distinct Client Proteins
The 13 Hsp70 proteins in humans act on unique sets of substrates with diversity often being attributed to J-domain-containing protein (Hsp40 or JDP) cofactors. We were therefore surprised to find drastically different binding affinities for Hsp70-peptide substrates, leading us to probe substrate specificity among the 8 canonical Hsp70s from humans. We used peptide arrays to characterize Hsp70 binding and then mined these data using machine learning to develop an algorithm for isoform-specific prediction of Hsp70 binding sequences. The results of this algorithm revealed recognition patterns not predicted based on local sequence alignments. We then showed that none of the human isoforms can complement heat-shocked DnaK knockout Escherichia coli cells. However, chimeric Hsp70s consisting of the human nucleotide-binding domain and the substrate-binding domain of DnaK complement during heat shock, providing further evidence in vivo of the divergent function of the Hsp70 substrate-binding domains. We also demonstrated that the differences in heat shock complementation among the chimeras are not due to loss of DnaJ binding. Although we do not exclude JDPs as additional specificity factors, our data demonstrate substrate specificity among the Hsp70s, which has important implications for inhibitor development in cancer and neurodegeneration.
- 20 January 2024
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 63 (3) , 251-263
Human Hsp70 Substrate-Binding Domains Recognize Distinct Client Proteins
The 13 Hsp70 proteins in humans act on unique sets of substrates with diversity often being attributed to J-domain-containing protein (Hsp40 or JDP) cofactors. We were therefore surprised to find drastically different binding affinities for Hsp70-peptide substrates, leading us to probe substrate specificity among the 8 canonical Hsp70s from humans. We used peptide arrays to characterize Hsp70 binding and then mined these data using machine learning to develop an algorithm for isoform-specific prediction of Hsp70 binding sequences. The results of this algorithm revealed recognition patterns not predicted based on local sequence alignments. We then showed that none of the human isoforms can complement heat-shocked DnaK knockout Escherichia coli cells. However, chimeric Hsp70s consisting of the human nucleotide-binding domain and the substrate-binding domain of DnaK complement during heat shock, providing further evidence in vivo of the divergent function of the Hsp70 substrate-binding domains. We also demonstrated that the differences in heat shock complementation among the chimeras are not due to loss of DnaJ binding. Although we do not exclude JDPs as additional specificity factors, our data demonstrate substrate specificity among the Hsp70s, which has important implications for inhibitor development in cancer and neurodegeneration.
- 13 October 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (3) , 266-267
A new road to STING activation
- 13 October 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (3) , 266-267
A new road to STING activation
- Open Access
- 5 October 2023
- Published by Springer Nature in Nature
- Vol. 622 (7984) , E3
Author Correction: Synthesis of portimines reveals the basis of their anti-cancer activity
- 5 October 2023
- Published by Springer Nature in Nature
- Vol. 622 (7984) , E3
Open AccessAuthor Correction: Synthesis of portimines reveals the basis of their anti-cancer activity
- 20 September 2023
- Published by Springer Nature in Nature
- Vol. 622 (7983) , 507-513
Synthesis of portimines reveals the basis of their anti-cancer activity
Marine-derived cyclic imine toxins, portimine A and portimine B, have attracted attention because of their chemical structure and notable anti-cancer therapeutic potential1,2,3,4. However, access to large quantities of these toxins is currently not feasible, and the molecular mechanism underlying their potent activity remains unknown until now. To address this, a scalable and concise synthesis of portimines is presented, which benefits from the logic used in the two-phase terpenoid synthesis5,6 along with other tactics such as exploiting ring-chain tautomerization and skeletal reorganization to minimize protecting group chemistry through self-protection. Notably, this total synthesis enabled a structural reassignment of portimine B and an in-depth functional evaluation of portimine A, revealing that it induces apoptosis selectively in human cancer cell lines with high potency and is efficacious in vivo in tumour-clearance models. Finally, practical access to the portimines and their analogues simplified the development of photoaffinity analogues, which were used in chemical proteomic experiments to identify a primary target of portimine A as the 60S ribosomal export protein NMD3.
- 20 September 2023
- Published by Springer Nature in Nature
- Vol. 622 (7983) , 507-513
Synthesis of portimines reveals the basis of their anti-cancer activity
Marine-derived cyclic imine toxins, portimine A and portimine B, have attracted attention because of their chemical structure and notable anti-cancer therapeutic potential1,2,3,4. However, access to large quantities of these toxins is currently not feasible, and the molecular mechanism underlying their potent activity remains unknown until now. To address this, a scalable and concise synthesis of portimines is presented, which benefits from the logic used in the two-phase terpenoid synthesis5,6 along with other tactics such as exploiting ring-chain tautomerization and skeletal reorganization to minimize protecting group chemistry through self-protection. Notably, this total synthesis enabled a structural reassignment of portimine B and an in-depth functional evaluation of portimine A, revealing that it induces apoptosis selectively in human cancer cell lines with high potency and is efficacious in vivo in tumour-clearance models. Finally, practical access to the portimines and their analogues simplified the development of photoaffinity analogues, which were used in chemical proteomic experiments to identify a primary target of portimine A as the 60S ribosomal export protein NMD3.
- 18 July 2023
- Published by Elsevier in Cell Chemical Biology
- Vol. 30 (9) , 1115-1134.e10
Hydroxyproline metabolism enhances IFN-γ-induced PD-L1 expression and inhibits autophagic flux
- 18 July 2023
- Published by Elsevier in Cell Chemical Biology
- Vol. 30 (9) , 1115-1134.e10
Hydroxyproline metabolism enhances IFN-γ-induced PD-L1 expression and inhibits autophagic flux